JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - EUPRAXIA PHARMACEUTICALS INC
Okay, good afternoon everybody. Thank you very much for joining me. My name is James Helliwell. I'm the founder and CEO of Eupraxia Pharmaceuticals, and thank you to Jeffries for hosting, and hope everybody got here safely despite the challenges of crossing the pond for a little bit there. So I'm going to walk through and tell you today about Eupaxia Pharmaceuticals, where we are, what we're doing, and some really exciting things that we have coming up, frankly, in the next few weeks. If there are, if I pace myself right, there'll be some time for some Q&A at the end. So first off is just the usual forward-looking statements. These are also on our website for those who want to get through all the detail there. So I want to start off by talking a little bit about what it is we do and how it is. We do it before we dive into the data. So my background, I'm a physician, cardiothoracic anesthesiologist. I lived my life in a critical care unit and doing heart transplants. And precision was everything that we strived for there. And so what you're looking at here is the technology that we developed to be able to be very precise with drugs in a variety of dimensions. Number one is locality. This is about getting the drug in exactly the tissue that you want, really only the tissuethat you want with zero order kinetics for a very long period of time. So you can control all of those aspects. In the diffusphere that you see here, what we've put is fluticasone propionate. Now, we've worked with lots of other APIs, but this is the one we're going to be really focused on today. And as you can see, a picture of the esophagus. We're going be talking about its use with an esophageal injection, which is very straightforward, in a disease called eosinophilic esophagitis. Now, when I went through medical school, this was not a disease. We didn't talk about it, yet we would see these patients. And these patients would describe great discomfort in swallowing. Difficulty swallower, pain on swallow, food getting stuck. You would then find them in the emergency room, you would rule out cancer, but you really didn't know what was wrong. Often they'd be diagnosed or misdiagnosed as we now realize with reflux disease. This disease is a complex type 2 inflammatory disease. Now we call it eosinophilic esophagitis and I've talked to the two physicians who named and discovered this disease and they've kind of acknowledged maybe they named it a little bit wrong. Eosinophils, which have been the target for many people from a therapeutic perspective, has really been shown to be relatively disconnected from, number one, patient symptoms, and number two, actually reversing fibrosis and the rigidity of the esophagus that really is causing all the symptoms for these patients. So fluticasone propionate, which is what we're using, is really upstream in this process. So while it has the ability to target eosinophils, mast cells. It also targets all of the inflammatory cytokines that are involved in this process, as well as is known to have an actual direct antifibrotic effect, which we know from its pulmonary applications. And so all of that is really us targeting in a very broad way, but hyper-localized only in the diseased tissue, what's actually happening and driving eosinophilic esophagitis. So I talked about how when I went through med school, we didn't have this disease. In 2022, this was still being considered an orphan indication by the FDA. Very quickly later in 2023, there was an acknowledgement it was no longer orphan. And the numbers jumped from as low as about 150,000 to being what you see there, 470,000. And so that 470,000 has now grown very, very dramatically. So we actually have some new numbers on here, which actually come from our own analysis, which we hired IQVIA to do for us. So what they did was actually a claims analysis. And they went out and looked for the specific diagnostic claim, so K20.0, which is eosinophilic esophagitis. And from 2022, when that last paper ended, looked throughout the United States. And you had to have that diagnostic code twice and be 30 to 180 days apart. So it's actually quite a conservative way of looking and trapping and tracking these patients. You'll notice the growth is steady. It's about 72,000 patients a year in the United States that this diagnostic code is growing. So by mid-26, that's 724,000 patient in the united states as of today. And that is going to continue to grow. And if it grows at the same rate, that puts you north of a million by 2030, which is when we anticipate and hope for a launch for this product. So a very big market with a remarkable number of patients in great need. So how is it that we deliver the diffusphere loaded with fluticasone to target all that inflammatory cascade? So by guideline, both American and European, these patients are supposed to be going for follow-up very frequently with their physicians. follow-up requires an endoscopy. Why? You want to be able to track not just symptoms of this disease, but progression of this desease. So are patients seeing a reduction in the inflammation? And most importantly, are they seeing a reduction in the fibrosis? And really what you don't want to see, which is the natural history of this disease, it is a progressive fibrostenotic disease, meaning it continues to get worse and worse and worst. So what happens is when you go in for that endoscopy today, they go down, they take pictures, they assess, and they take biopsies. Well, knowing that, we said, let's piggyback on top of a procedure you're already going for, the payer is already paying for, and you have accepted any risk of that procedure from a patient and physician perspective. And instead, let'S piggyback On that. We add 10 minutes or less to that procedure, which is easily absorbed into the landscape of how these physicians practice. And gastroenterologists are proceduralists and very skilled proceduralists. So they like doing things. So doing these injections is second nature for them. Patients can't feel it. There's no nerve endings there to feel injections. So it really is a very seamless procedure. And one that, although for those of us who may not have had an endoscopy, might sound a little bit trepidatious, the reality is for patients, they really line up for this. And it's interesting. When we did the RESOLVE trial, which I'm going to show you some data from Part 1 today, we really saw this. So this trial recruited, when we looked at all the trials that had been done in EOE, and we looked AT how many patients they recruited, how many sites they had, and how long they took, you very quickly figure out how many site per patient per month. We recruited at twice the rate of any other EOES trial, which reflected both an interest from the patients and an interest in support from the physicians. So in this part one, it was all about trying to triangulate to the dose and how many injections we needed. Did we need just four? Did we needs 20, which covers the whole esophagus? What we realized from this data was that full coverage of the esophageus gave the best and most consistent results, and that we wanted to have the highest dose that we could possibly see there. This was all PK, this was about safety, but it was also about efficacy. So when we talk about efficacy, it's really the hardest thing to hit. And when you look, you will have seen, if you follow this space, a lot of products in development that have had a histologic outcome, particularly one of reducing eosinophils. What they haven't done is make patients feel better in a really meaningful way. The Straumann dysphagia index, which was the first validated tool, actually measures clinical remission. So on this nine-point scale, that's an improvement of at least three points. and most people enter at about six. So it means it's a greater than 50% improvement from your baseline. So it's very stringent requirement to hit. When we look at products that it looked at this, there's only one approved product that looked at metric in a phase two trial. And they saw 39% of their patients at 10 weeks achieve clinical remission. Here, what you're seeing, oh, sorry, this is actually PK. This is our pharmacokinetics, apologies. And so essentially what you are looking at here is zero-order kinetics. So after 48 hours of adjustment period from the injection, you can see that the same amount of drug is being delivered 24 hours a day, seven days a week for 365 days. And so a really unique profile, all from that single injection given at day zero. The other thing I'll note is that at the top, what you can See there, that is for the 20-some-odd million people a day who take an inhaled fluticasone. That's the amount of fluticazone they have in their plasma, and we're well below that level, meaning that both regulatory path as well as safety expectations can be really well grounded against that. So here now we get to clinical advocacy. You can tell I was excited about making patients feel better. So what you can see here is within two weeks, we have 40% of people in clinical remission, and it continues to get better.So by eight weeks, you're seeing we're close to 60%. We're close to 80% by six months and 64% of patients are still in clinical remission at 52 weeks, all from that single dose given on that first day. This has been remarkable and anecdotally we've been having patients who've gone past their 12 months, phoning their primary investigator at about 14 15 months, say please, I now have symptoms I can't eat, I've been eating normally I've bee eating steak, I'm eating bread can I please come back and get another dose? Now, we don't yet have a way to get them another dose, but that's coming very, very shortly. So one of the interesting things you're probably wondering is, so what's happening between week two and month six? What's going on that the patients continue to get better to that degree? The other thing is we are not just seeing symptom improvement and ease of swallowing and food not getting stuck. We are also seeing the pain on swallwing reduced very dramatically. So here you see about 65% of people have severe and or moderate to severe pain on swallowing. Within about six weeks, we flipped that where 75% of people have essentially none or very little, very mild pain on swallowering. And that maintains all the way out to a year. And even those who had severe, essentially other than one patient at nine months, the worst becomes moderate. So everybody is actually getting better and we're holding that again all the way out to a year. So again, why such a big difference? So I want to talk for a minute about this scale. This is the EOEHSS. So this is the histology scoring system. So we take 20 biopsies throughout the esophagus. And so we get a very dense picture of what's actually happening. This is broken into eight scores. Four of those scores are about inflammation. And when they look at inflammation, it's primarily actually about eosinophils. So it is not an eosinfil count, which tells you very little about what's happening. Three of the eight scores are telling you about the pathologic findings in the tissue of eosinofils. Very different than just counting them. And then the other four are all about fibrosis. They're telling you about the structural abnormality that's in the esophagus. What you see here is as we ramped up in dose, we see more and more improvement over time on this. This is a one point scale. People were entering this with a baseline of about 0.6. And so what you're seeing is getting anywhere from 50% to 90% improvement depending on the dose and on the patients here. And so this though takes time. You can see that at four weeks, We are not the same as we are at 12 weeks. And then you can see we last still at nine months. We don't have a 24 or 52. That does in the next trial. And so what we're seeing is a very fast response. What is it? That's the anti-inflammatory effect. That delayed response, that is reversal of fibrosis. So not just controlling advancing of fibcrosis, actually reversing fibrosus. Patients are coming in with rings and strictures, and those rings and restrictures are actually dissipating. given the time if i get through this quickly enough i'll make a comment on what physicians are telling us about that this is now looking at eosinophil count if you actually look through most studies and look really carefully what you'll notice is a total disconnect between clinical outcome and peak eosinfil count reduction the most dramatic example there is a siglidate inhibitor that did the best job probably that anybody's done at actually reducing eosinophil count. 90% of patients had PEC under 6. Clinical outcome, no different than placebo. In fact, the low dose was worse than placebo, so PEC count does not equal patients getting better. This data, we are reducing PEC account. It's great. When we look for the patient connection, there is no connection between those patients who have the best PEC response and the clinical response. EOHSS, that's different. There we have a statistically significant connection between reduction in EOHHS and improvement in patient symptoms. So that's sort of the, again, the disease perhaps not named exactly right. Also in this, we've seen really great safety. So candidiasis, if you know this disease, it's PPIs, it's oral steroids, and then it's biologics. The oral steroids while they often work very well. Compliance is a very big problem, and part of that compliance is people get oropharyngeal candidiasis, so a fungal infection. We had zero patients in this trial who had oropharyngeal candidiosis, even though we're following for a very long period of time. No cortisol suppression, no adrenal suppression, no change in glucose, including in diabetic patients. Extremely well-tolerated in procedure, extremely well tolerated. So what's coming? Part two of this trial is coming. Part two is we took the top two doses of the last trial and put them against a placebo. Now the placebo is 20 sham injections so they are getting the exact same volume of everything but the drug and then we follow for six months. We do scopes every three months, so baseline 3, 6, 9, and 12, and we look and track everything along all of that. We are having an interim data analysis, a cut. This isn't a registrational trial, so we're spending no alpha on it. That interim analysis is coming within the next several weeks, where we're going to be able to see about half the trial at the six-month time period, as well as more patients at earlier time points and some patients already all the way out to a year because a once-a-year dosing is a critical feature of this product. As we look to that data that's coming first and really importantly, this is actually blinded safety. So if you've looked at a lot of EOE trials, you'll notice that any treatment emergent adverse events is actually a little bit at the lower end of what people see, which is usually high 70s, low 80s. We're in the 70s here. These are very sort of typical things that you'll see in treatment emergent adverse events. What you'll notice is only one patient across the trial has had oropharyngeal candidiasis. We don't know yet whether that's in placebo or active. We'll make the assumption that they're in The Active Arm. The injection procedure, we have done over 3,000 individual injections so far without any complications you might associate with injections. So, for example, things like perforation, abscesses, hematomas, bleeding, none of that has occurred across any of those patients, and this trial is fully recruited. So that means all those procedures are done, and any effects you would have seen would have already happened. SAEs, there were six patients who had SAEs. None of them were deemed to be related to the study drug by the PIs. So just, again, a really well-tolerated drug such as we're seeing so far. what will interim data report so um in december we're going to have the first 60 patients to 24 weeks we're gonna have the 1st 20 patients to 52 weeks and we're g oing to be looking at symptoms so that is the sdi which we looked at the dsq which we haven't talked about yet but is what you will have noticed the approved products today have used as their patient reported outcome it's actually asking exactly the same questions for the most part as the SDI. It asks them in a different way. The SDI is a seven-day recall that you ask once. The DSQ is asking you every single day for 14 days. It's actually quite a noisy endpoint. Standard deviation is fairly large. The reason it's fairly large is first, you only need to answer eight of the 14 days in order for you to have a score. If you answer seven or less, you get a zero, and you're out, and there's no data for and you'll notice across trials 15 to 20 percent of the people actually don't answer their questions so you actually miss data that creates noise with that endpoint the other thing is is that if you answer eight or nine days there's imputation for the other days so what that means is it magnifies good and it magnifies bad so if you see a large standard deviation that's why so we don't expect in symptoms to actually have statistical significance but we do expect to have strong directional trend because this is only 20 patients and if you look at some of the trials, they're using 100, 120 patients in order to get statistical significance. Were we to have statistical significance at any end point in either of these, that would be hitting out of the park so to speak. My sports analogies are always tells me, my team tells me but I think that one's a safe one. When we look at histology, EOHSS, really what we're looking at there is both the pathologic features of eosinophils, as well as the eosinofil count, again, that fibrosis, they're also not really powered to be able to have statistical significance. So if we do, it means we are having a very meaningful effect in terms of both size and also reduction in standard deviation, which is really important. We want to see a very consistent response across patients so that we're helping as many as we can. And endoscopy becomes that truth teller between those two. So we have symptoms and we have histology. So we're looking at biopsies. EREFs is endoscopically the physician looks in and use it as a validated tool to measure inflammatory signs and also structural signs. What you want to see is consistency across those three. If you hit one endpoint dramatically and you don't hit the others, it makes you wonder what's happening with your drug. You want to see that biologic consistency across all three of those endpoints it's what we showed in part one it's what we hope to continue to show in part two um and so we look to this really being validating driving us forward into our end of phase two meeting in the first part of 2027 on the back of this interim data the other comment i'll make on this study is based on the durability that we've seen to date based on the safety that's been seen uh and the part one efficacy uh we just did a major protocol amendment we now follow these patients for two years. So we can really see how far beyond 12 months they are getting and certainly seeing, we already see that 12-month response, but been able to see past, to be able to time the second dose. So, we ideally think it'll be done at 12 months before you begin to get symptomatic or fibrotic again. Again, data will really drive that, and we're going to have a lot of that to talk about here. I want to make one more comment here, which is about what we're seeing from a fibrotic perspective and just how important it is. So it was actually the investigators who started coming back to us watching these patients in these trials. And they were seeing patients come in with really bad strictures, and those strictures just disappearing. And so they started to come first. The first thing they said was, we're surprised to see the amount of resolution of strictures. But the second thing they did is, if you can do this here, there are other places we want to take this. And so benign esophageal strictures, which today there are no on-label treatments for. There are 500,000 patients in the United States who are getting balloon endoscopies and literally tearing open the esophagus. Some patients as frequently as every week or two weeks just so they can eat. And some of them swallow a bougie at home just so They can have dinner. The standard of care is a triamcinolone, so steroid injection given submucosally right after the balloon. Really good prospective trials say that works, but only for a short period of time. So they immediately said, we want to use it in those 500,000 patients instead of a drug that's lasting days. And they also came to us about fibrostinosynchrones. So real opportunities. And again, it's the same GIs, same call point, doing it the same way in their clinic, all submucosal injections, same catheter. So from a commercial perspective, very, very efficient. Recognizing just a few minutes left here, I want to talk about where we are in EOE. So when we think about that million patients in eosinophilic esophagitis, first-line therapy today, proton pump inhibitors, we know that 60% of those patients progress and progress fairly rapidly as they develop fibrosis. So even if their symptoms are controlled, if you're actually tracking them, they're often developing fibrotic symptoms because it's progressive. You then move to the oral corticosteroids. steroids. That's the space we're looking to really take, to not have to have patients not have to take something twice a day, not have oral candidiasis, and frankly non-compliance. Both European and American literature is showing non-compliance of between 70 and 90 percent with oral steroids over the long term. An intermittent use with the paper just published about six weeks ago shows that it is no different at all from just taking placebo. So that's an for patients and payers and physicians. Third line is the biologics. So the biologicks are today taking up about 8% of the market. If we grow that to 25% you assume that you've got 30% on PPIs. That's leaving you with 45% of that market really unaddressed where a once a year corticosteroid injection that happens to also meet the commercial requirements of a physician the way they practice buy and build economics. This is a medical benefit not a pharmacy benefit as well as increased procedural fees really means trying to meet the needs of the physician, the payer, and most importantly, the patient. Lastly, and I think I did use up all the time, so there unfortunately won't be Q&A, but happy to connect with anybody afterwards. As you can see here, in terms of cash and short-term investments, we have cash until Q3 of 2028. So that allows us not just to finish the trial we're doing, it also allows us to start the Phase 3 program. We will need to fund to finish the phase three and get to NDA. We estimate that's about $125 million as an incremental raise over what we have today. Included in use of proceeds today and that timeline to Q3 2028 is the launch and execution and finish of a benign esophageal stricture phase two trial. So overall, we're really looking forward to the interim data that we have upcoming. And if you need anything on any of this, we remain available, although we will be going quiet fairly soon. There is lots of information on our website, including I made a brief mention of the commercial. There's a whole webinar there where you can also see the injections themselves. So as one of our patients from the study being done by a PI, you'll see it's 5 to 10 seconds per injection, very quick, very simple. And so I encourage you to look at that. and so with that I will say thank you very much for being here really appreciate everybody's time hope you have a wonderful conference and a great time in London thank you
- Company
- EUPRAXIA PHARMACEUTICALS INC
- Keywords
- EUPRAXIA PHARMACEUTICALS INC